Clinical Trial Update: A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assesses whether the Recombinant Zoster Vaccine influences the incidence of dementia among adults aged 76 and older in Finland.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia
• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 4 | Status: NOT_YET_RECRUITING